Found: 74
Select item for more details and to access through your institution.
Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 7, p. 3075, doi. 10.1007/s00432-022-04185-w
- By:
- Publication type:
- Article
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial.
- Published in:
- Clinical Breast Cancer, 2024, v. 24, n. 5, p. 421, doi. 10.1016/j.clbc.2024.02.012
- By:
- Publication type:
- Article
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2020, v. 20, n. 2, p. 174, doi. 10.1016/j.clbc.2019.06.016
- By:
- Publication type:
- Article
Emerging Therapeutics for Patients with Triple-Negative Breast Cancer.
- Published in:
- Current Oncology Reports, 2021, v. 23, n. 5, p. 1, doi. 10.1007/s11912-021-01038-6
- By:
- Publication type:
- Article
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 4, p. 1386, doi. 10.3390/ijms21041386
- By:
- Publication type:
- Article
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.
- Published in:
- Breast Cancer Research & Treatment, 2024, v. 203, n. 3, p. 497, doi. 10.1007/s10549-023-07159-9
- By:
- Publication type:
- Article
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
- Published in:
- Breast Cancer Research & Treatment, 2024, v. 203, n. 2, p. 351, doi. 10.1007/s10549-023-07116-6
- By:
- Publication type:
- Article
Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 192, n. 2, p. 457, doi. 10.1007/s10549-022-06525-3
- By:
- Publication type:
- Article
Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D).
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 185, n. 1, p. 107, doi. 10.1007/s10549-020-05915-9
- By:
- Publication type:
- Article
Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 181, n. 1, p. 199, doi. 10.1007/s10549-020-05617-2
- By:
- Publication type:
- Article
A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 179, n. 1, p. 161, doi. 10.1007/s10549-019-05453-z
- By:
- Publication type:
- Article
Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO).
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 176, n. 3, p. 607, doi. 10.1007/s10549-019-05259-z
- By:
- Publication type:
- Article
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 177, n. 1, p. 103, doi. 10.1007/s10549-019-05284-y
- By:
- Publication type:
- Article
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 174, n. 1, p. 27, doi. 10.1007/s10549-018-5055-9
- By:
- Publication type:
- Article
Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231183679
- By:
- Publication type:
- Article
Molecular markers of head and neck squamous cell carcinoma: Promising signs in need of prospective evaluation.
- Published in:
- Head & Neck, 2006, v. 28, n. 3, p. 256, doi. 10.1002/hed.20326
- By:
- Publication type:
- Article
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer.
- Published in:
- PLoS ONE, 2013, v. 8, n. 8, p. 1, doi. 10.1371/journal.pone.0066848
- By:
- Publication type:
- Article
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
- Published in:
- European Heart Journal, 2022, v. 43, n. 41, p. 4229, doi. 10.1093/eurheartj/ehac244
- By:
- Publication type:
- Article
HER2-Low Breast Cancer: Where Are We?
- Published in:
- Breast Care, 2022, v. 17, n. 6, p. 533, doi. 10.1159/000527391
- By:
- Publication type:
- Article
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00452-8
- By:
- Publication type:
- Article
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer.
- Published in:
- NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-021-00277-x
- By:
- Publication type:
- Article
Medical Oncology Education in Europe: Equipping Medical Oncologists to Provide the Best Care for Patients with Cancer.
- Published in:
- Oncology Research & Treatment, 2023, v. 46, n. 3, p. 72, doi. 10.1159/000529128
- By:
- Publication type:
- Article
Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 21, p. 5467, doi. 10.3390/cancers14215467
- By:
- Publication type:
- Article
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.
- Published in:
- Cancers, 2021, v. 13, n. 11, p. 2824, doi. 10.3390/cancers13112824
- By:
- Publication type:
- Article
The Exciting New Field of HER2-Low Breast Cancer Treatment.
- Published in:
- Cancers, 2021, v. 13, n. 5, p. 1015, doi. 10.3390/cancers13051015
- By:
- Publication type:
- Article
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. 1, doi. 10.1177/1758835919827714
- By:
- Publication type:
- Article
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835919827714
- By:
- Publication type:
- Article
Targeted therapies in breast cancer: are heart and vessels also being targeted?
- Published in:
- 2012
- By:
- Publication type:
- journal article
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial.
- Published in:
- Ecancermedicalscience, 2022, v. 16, n. 1366-1414, p. 1, doi. 10.3332/ecancer.2022.1379
- By:
- Publication type:
- Article
Phosphoethanolamine and the danger of unproven drugs.
- Published in:
- Ecancermedicalscience, 2016, v. 10, n. 674-708, p. 1, doi. 10.3332/ecancer.2016.681
- By:
- Publication type:
- Article
Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25.
- Published in:
- Ecancermedicalscience, 2014, v. 8, n. 413-446, p. 1, doi. 10.3332/ecancer.2014.425
- By:
- Publication type:
- Article
Ovarian Suppression: Early Menopause and Late Effects.
- Published in:
- Current Treatment Options in Oncology, 2024, v. 25, n. 4, p. 523, doi. 10.1007/s11864-024-01190-8
- By:
- Publication type:
- Article
Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
European Society of Cardiology Core Curriculum for cardio‐oncology.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 4, p. 754, doi. 10.1002/ejhf.3102
- By:
- Publication type:
- Article
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.
- Published in:
- European Journal of Heart Failure, 2011, v. 13, n. 1, p. 1, doi. 10.1093/eurjhf/hfq213
- By:
- Publication type:
- Article
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
- Published in:
- European Heart Journal - Cardiovascular Imaging, 2022, v. 23, n. 10, p. e333, doi. 10.1093/ehjci/jeac106
- By:
- Publication type:
- Article
Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative Data.
- Published in:
- Clinical Epidemiology, 2023, v. 15, p. 559, doi. 10.2147/CLEP.S400071
- By:
- Publication type:
- Article
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.
- Published in:
- 2016
- By:
- Publication type:
- journal article
<sup>18</sup>F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO.
- Published in:
- Journal of Nuclear Medicine, 2013, v. 54, n. 11, p. 1862, doi. 10.2967/jnumed.112.119271
- By:
- Publication type:
- Article
p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.
- Published in:
- International Journal of Oncology, 2018, v. 52, n. 2, p. 424, doi. 10.3892/ijo.2017.4212
- By:
- Publication type:
- Article
Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis.
- Published in:
- Frontiers in Oncology, 2018, p. 1, doi. 10.3389/fonc.2018.00156
- By:
- Publication type:
- Article